Orexo’s Annual Report for 2015 released


Uppsala, Sweden – March 22, 2016 – Orexo’s Annual Report for the 2015 fiscal
year has been published and can be downloaded from the investor section of the
company’s homepage www.orexo.com/en/Investor-Relations/.

For further information, please contact:
Lena Wange, IR & Communications Manager
Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com

About Orexo
Orexo is a specialty pharmaceutical company commercializing its proprietary
product Zubsolv® for maintenance treatment of opioid dependence in the US.
Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s
unique knowledge and expertise in sublingual drug delivery. R&D is focusing on
reformulation of known substances to new improved products that meet great unmet
medical needs by using its patented proprietary technologies. Orexo’s share is
listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs
on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in
Uppsala, Sweden.

For information about Orexo please visit www.orexo.com.

Attachments

03222619.pdf Orexo Press_release_Annual Report 2015 released_2016-03-22.pdf